Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34.157
Filtrar
1.
Croat Med J ; 65(4): 313-327, 2024 08 31.
Artigo em Inglês | MEDLINE | ID: mdl-39219195

RESUMO

AIM: To assess the relationship between the attitudes of general practitioners/family medicine doctors (GP/FD) and of their patients toward industry-sponsored clinical research. METHODS: A cross-sectional survey included volunteer GPs/FDs who then enrolled and interviewed their patients. Data were analyzed in hierarchical models (patients nested in GPs/FDs, nested in countries/regions). RESULTS: A total of 201 GPs/FDs from nine European countries responded to the invitation and enrolled 995 of their patients. We observed mild associations between some of the GPs/FDs' attitudes (general opinion on sponsored clinical studies, appreciation of the general values of such studies, views about the importance of participant protection/privacy) and some of the patients' attitudes (appreciation of the general values and of risks associated with sponsored clinical studies, importance assigned to potential personal benefits from participation). We observed no association between GPs/FDs' attitudes and patients' willingness to participate in such studies. However, willingness to participate increased with higher patients' appreciation of the general values of sponsored studies, decreased with higher patients' appreciation of associated risks, and showed a quadratic trend across the levels of importance assigned by patients to potential personal benefits (willingness was higher when the assigned importance was very low or very high). More importance to GP/FD's advice in this respect was assigned by patients who assigned more importance to potential personal benefits, who were better educated, and who resided in rural/suburban dwellings. CONCLUSIONS: In the present convenience sample, lay-person attitudes about and willingness to participate in industry-sponsored clinical studies were associated with the attitudes of their GPs/FDs.


Assuntos
Atitude do Pessoal de Saúde , Clínicos Gerais , Humanos , Estudos Transversais , Europa (Continente) , Feminino , Masculino , Clínicos Gerais/psicologia , Pessoa de Meia-Idade , Adulto , Indústria Farmacêutica , Médicos de Família/psicologia , Inquéritos e Questionários
2.
Chimia (Aarau) ; 78(7-8): 499-512, 2024 08 21.
Artigo em Inglês | MEDLINE | ID: mdl-39221845

RESUMO

The endocannabinoid system (ECS) is a critical regulatory network composed of endogenous cannabinoids (eCBs), their synthesizing and degrading enzymes, and associated receptors. It is integral to maintaining homeostasis and orchestrating key functions within the central nervous and immune systems. Given its therapeutic significance, we have launched a series of drug discovery endeavors aimed at ECS targets, including peroxisome proliferator-activated receptors (PPARs), cannabinoid receptors types 1 (CB1R) and 2 (CB2R), and monoacylglycerol lipase (MAGL), addressing a wide array of medical needs. The pursuit of new therapeutic agents has been enhanced by the creation of specialized labeled chemical probes, which aid in target localization, mechanistic studies, assay development, and the establishment of biomarkers for target engagement. By fusing medicinal chemistry with chemical biology in a comprehensive, translational end-to-end drug discovery strategy, we have expedited the development of novel therapeutics. Additionally, this strategy promises to foster highly productive partnerships between industry and academia, as will be illustrated through various examples.


Assuntos
Química Farmacêutica , Descoberta de Drogas , Endocanabinoides , Endocanabinoides/metabolismo , Endocanabinoides/química , Humanos , Indústria Farmacêutica , Monoacilglicerol Lipases/metabolismo , Monoacilglicerol Lipases/antagonistas & inibidores , Desenvolvimento de Medicamentos , Academia
4.
Nat Biotechnol ; 42(9): 1473, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39271827
5.
7.
Nat Biotechnol ; 42(9): 1330, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39271841
8.
PLoS One ; 19(9): e0310236, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39255278

RESUMO

This study examined the factors influencing green accounting and reporting practices (GARPs) in Bangladesh's pharmaceutical and textile industries. Hence, it draws upon disclosure theory to disclose relevant information in the context of environmental accounting and encourages them to boost their environmental performance. It utilized content analysis from 13 pharmaceuticals and 22 textiles data from Dhaka stock exchange (DSE) listed companies of Bangladesh and applied quantitative methods for comparative analysis. The findings showed that GARPs are influenced by firm characteristics and external factors rather than organizational performance, and eleven environmental indicators (separately) have a lower mean of less than 0.50 in both industries. Firms' general characteristics (FFGC) are noteworthy factors that exhibit a negative coefficient for both the pharmaceutical and textile sectors but hold a robust impact on the GARPs, with P = 0.007 and 0.003, respectively. The statistical significance of environmental factors (EFs) applies to the textile sector p = 0.000. Implementing GARPs in the pharmaceutical industry proved more effective than in the textile sector, offering valuable support to managers in expediting environmental practices in Bangladesh's textile industry.


Assuntos
Indústria Farmacêutica , Indústria Têxtil , Bangladesh , Humanos , Têxteis
10.
Nihon Yakurigaku Zasshi ; 159(5): 300-303, 2024.
Artigo em Japonês | MEDLINE | ID: mdl-39218674

RESUMO

An issue in drug discovery research at pharmaceutical companies is the decline in the probability of market launch, and there is a need to improve the proof-of-concept (POC) acquisition rate by further improving clinical predictability. For this purpose, we need to deepen our understanding of human pathophysiology, and to make efficient of drug discovery research by utilizing human samples and data due to the change in mindset from "animals" to "humans" at the drug discovery research stage. In particular, with the aim of improving the efficiency of drug discovery research by utilizing human samples/data, we have established a human sample utilization support capability, then we are supporting the acquisition of appropriate human samples/data to meet each drug research need with collecting information on organizations that can provide various human samples and accumulating know-how on obtaining human samples/data. In addition, we have built a one-stop support system for surveying human samples/data, negotiating, and contracting with the organizations, obtaining ethical committee approvals, importing samples, and dealing with customs clearance. As results, our researchers can obtain high-quality human samples/data to meet their research needs rapidly/easily. By establishing this capability, the number of the research projects that implement target validation, pharmacological evaluation, BM identification, and patient stratification, etc. using human samples/data from the early stage of drug discovery, has increased, and then, the evidence obtained by using human samples/data contribute to create drug candidates with high probability of clinical effect. We will introduce our activities while showing the support flow that was actually constructed.


Assuntos
Descoberta de Drogas , Indústria Farmacêutica , Humanos
11.
Indian J Pharmacol ; 56(4): 285-289, 2024 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-39250626

RESUMO

ABSTRACT: The manuscript summarizes the outcomes of a one-day conference by the South Asian College of American College of Clinical Pharmacology (SAC-ACCP) in July 2023, at Bhopal. The theme of the conference was "Advancing pediatric drug development in South Asia." SAC-ACCP organized this event in Bhopal to foster the discipline of clinical pharmacology and to motivate researchers and physicians in the in the central part of India. The conference featured presentations on regional approaches to pediatric drug development in Asia by pediatric scientific experts from the pharmaceutical industry, regulatory agencies, as well as independent consultancies. The speakers highlighted several important aspects of the evolving regulatory landscape in India and proposed numerous actionable steps in acceleration of pediatric drug development. This commentary provides insights from presentations and the panel discussion at this conference and also makes an attempt to connect to similar discussions that occurred at the SAC-ACCP drug development conference in 2017.


Assuntos
Desenvolvimento de Medicamentos , Pediatria , Humanos , Criança , Ásia , Índia , Indústria Farmacêutica , Farmacologia Clínica/tendências , Ásia Meridional
12.
Health Aff (Millwood) ; 43(9): 1284-1289, 2024 09.
Artigo em Inglês | MEDLINE | ID: mdl-39226496

RESUMO

The rising price of branded drugs has garnered considerable attention from the public and policy makers. This article investigates the complexities of pharmaceutical pricing, with an emphasis on the overlooked aspects of manufacturer rebates and out-of-pocket prices. Rebates granted by pharmaceutical manufacturers to insurers reduce the actual prices paid by insurers, causing the true prices of prescriptions to diverge from official statistics. We combined claims data on branded retail prescription drugs with estimates on rebates to provide new price index measures based on pharmacy prices, negotiated prices (after rebates), and out-of-pocket prices for the commercially insured population during the period 2007-20. We found that although retail pharmacy prices increased 9.1 percent annually, negotiated prices grew by a mere 4.3 percent, highlighting the importance of rebates in price measurement. Surprisingly, consumer out-of-pocket prices diverged from negotiated prices after 2016, growing 5.8 percent annually while negotiated prices remained flat. The concern over drug price inflation is more reflective of the rapid increase in consumer out-of-pocket expenses than the stagnated inflation of negotiated prices paid by insurers after 2016.


Assuntos
Custos de Medicamentos , Gastos em Saúde , Humanos , Custos de Medicamentos/tendências , Gastos em Saúde/tendências , Estados Unidos , Indústria Farmacêutica/economia , Seguradoras/economia , Medicamentos sob Prescrição/economia , Comércio/economia , Comércio/tendências , Seguro de Serviços Farmacêuticos/economia
13.
Lakartidningen ; 1212024 Aug 27.
Artigo em Sueco | MEDLINE | ID: mdl-39228227

RESUMO

The paper outlines the role of the Swedish Medical Products Agency (Läkemedelsverket) in managing medicine shortages. The agency receives reports from pharmaceutical companies, investigates causes, and disseminates information to pharmacies, healthcare providers, and the public. While focusing on mitigating shortages, the agency clarifies its non-involvement in manufacturing or sales decisions. Pharmaceutical companies must promptly report shortages, with sanctions enforced for non-compliance. Various measures, including regulatory actions, interchangeable medicines, temporary dispensations, and licensing, are employed to address shortages. Additionally, the agency advocates for stable national drug supply preparedness, emphasizing collaboration and governmental intervention.


Assuntos
Indústria Farmacêutica , Suécia , Humanos , Preparações Farmacêuticas/provisão & distribuição
14.
Healthc Policy ; 19(4): 70-80, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-39229664

RESUMO

Background: Medical school deans wield considerable influence over research, clinical and educational missions at their institutions. This study investigates conflict of interest (COI) of Canadian medical school deans. Method: The websites of all 17 Canadian medical schools were searched for any mention of relationships between deans and pharmaceutical or medical device companies. Results: No COIs were discovered for 11 of the deans. Six had COIs, including participating in research funded by pharmaceutical companies and received consulting and speaker fees. Discussion: A minority of deans had COIs with healthcare industry companies. Whether deans' COIs affect policies at the medical schools they lead should be the subject of further investigation.


Assuntos
Conflito de Interesses , Faculdades de Medicina , Canadá , Estudos Transversais , Humanos , Docentes de Medicina , Indústria Farmacêutica
15.
Perspect Biol Med ; 67(3): 325-336, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39247927

RESUMO

Many factors determine whether and when a class of therapeutic agents will be successfully developed and brought to market, and historians of science, entrepreneurs, drug developers, and clinicians should be interested in accounts of both successes and failures. Successes induce many participants and observers to document them, whereas failed efforts are often lost to history, in part because involved parties are typically unmotivated to document their failures. The GLP-1 class of drugs for diabetes and obesity have emerged over the past decade as clinical and financial blockbusters, perhaps soon becoming the highest single source of revenue for the pharmaceutical industry (Berk 2023). In that context, it is instructive to tell the story of the first commercial effort to develop this class of drugs for metabolic disease, and how, despite remarkable early success, the work was abandoned in 1990. Told by a key participant in the effort, this story documents history that would otherwise be lost and suggests a number of lessons about drug development that remain relevant today.


Assuntos
Desenvolvimento de Medicamentos , Peptídeo 1 Semelhante ao Glucagon , Humanos , Peptídeo 1 Semelhante ao Glucagon/história , Desenvolvimento de Medicamentos/história , História do Século XX , Hipoglicemiantes/história , Hipoglicemiantes/uso terapêutico , Indústria Farmacêutica/história , Obesidade/história , Obesidade/tratamento farmacológico
16.
Pharm Res ; 41(8): 1547-1555, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-39107515

RESUMO

This paper reviews the accelerated development of pharmaceuticals, exploring past, present, and future perspectives. It provides a historical overview of early strategies used to expedite development, beginning with initiatives from the 1990s. The work of Gardner and Byrn in accelerated development analysis during this era is highlighted. The narrative progresses to the 2000s, discussing the emergence of PK/PD in accelerating pharmaceutical development. The paper further examines case studies in the accelerated development field, including the INDIGO and Chorus programs. It concludes with an analysis of the current state of the field, referencing the NIPTE conference, which focused on the industrial perspective of accelerated development. Additionally, the paper outlines strategies for the rapid development of Solid Lipid Nanoparticle manufacturing and vaccine production.


Assuntos
Desenvolvimento de Medicamentos , Nanopartículas , Animais , Humanos , Desenvolvimento de Medicamentos/história , Desenvolvimento de Medicamentos/métodos , Desenvolvimento de Medicamentos/tendências , Indústria Farmacêutica/história , Indústria Farmacêutica/métodos , Indústria Farmacêutica/tendências , História do Século XX , História do Século XXI , Nanopartículas/química , Nanopartículas/história , Preparações Farmacêuticas/química , Preparações Farmacêuticas/história , Vacinas/história
19.
BMC Public Health ; 24(1): 2153, 2024 Aug 08.
Artigo em Inglês | MEDLINE | ID: mdl-39118033

RESUMO

BACKGROUND: More than 263,000 individuals died due to prescription opioid misuse between 1999 and 2020. Between 2013 and 2015 alone, pharmaceutical companies spent over $39 million to market opioids to over 67,000 prescribers. However, there is still limited information about differences in provider responses to promotions for medications. In this study we investigated and evaluated strategies used by opioid manufacturers to encourage overprescribing, specifically focusing on oncology. METHODS: We conducted a retrospective review of opioid industry documents released in litigation between 1999 and 2021. We began with a preliminary search for business plans in a subset of collections that identified key terms and phrases. These search terms were then used to narrow the investigation, which ultimately focused on Insys Therapeutics, and how they targeted oncology providers as well as patients with cancer pain. RESULTS: We found that, overall, Insys sought to market to institutions with fewer resources, to less experienced and high-volume providers, and directly to cancer patients, with the goal of encouraging increased opioid prescribing and use. CONCLUSIONS: Our research revealed gaps in provider training that may make some providers more susceptible to pharmaceutical marketing. Developing and promoting continuing education courses for providers that are free from conflicts of interest, particularly at smaller institutions, may be one step towards reducing opioid overprescribing and its associated harms.


Assuntos
Analgésicos Opioides , Indústria Farmacêutica , Humanos , Analgésicos Opioides/uso terapêutico , Estudos Retrospectivos , Padrões de Prática Médica/estatística & dados numéricos , Prescrição Inadequada/prevenção & controle , Pessoal de Saúde/psicologia
20.
Soc Sci Med ; 356: 117158, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39094389

RESUMO

Scholars have identified notable similarities between the political strategies employed by health-harming industries. This includes similarities in the narratives employed by industry actors seeking to oppose public health regulations that threaten their commercial interests. This study seeks to examine the use of a specific concept - the balance metaphor - in the policy discourses of two health-harming industries. Namely, the pharmaceutical industry implicated in the prescription opioid crisis in the US, and the UK gambling industry, whose products and practices are associated with a serious, but largely neglected, series of harms. We first review research on metaphors, demonstrating how this provides additional theoretically-informed concepts with which to understand how industry discourse circumscribes the terrain of policy debates in ways amenable to commercial interests. Building from these insights, we conducted a rhetorical analysis, examining how the concept of balance is employed by different actors in distinct contexts to shape understandings of the social and policy problems associated with gambling and opioid products and to promote industry-favourable regulatory responses to these. This brings a micro-level of analysis to supplement previous meso- and macro-level scholarship in this space. We use our findings to argue that the depoliticization of the policy process and objectivization of the policy space - in ways that obscure its contingent and political nature - through discourses of balance is itself an arch political act. Examining the metaphors used in policy debates and their functions provides important insights that can be used to inform the construction of counter-narratives to industry-favourable discourses, including the creative use of novel metaphors in the service of public health goals.


Assuntos
Indústria Farmacêutica , Jogo de Azar , Metáfora , Política , Humanos , Jogo de Azar/psicologia , Estados Unidos , Reino Unido , Indústria Farmacêutica/legislação & jurisprudência , Analgésicos Opioides , Política de Saúde
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA